Biogen and Eisai Report Strong Real-World Uptake of Leqembi for Early Alzheimer's Disease

Biogen and Eisai today reported strong real-world uptake of Leqembi (lecanemab-irmb) following its traditional FDA approval for early Alzheimer's disease. More than 10,000 patients have initiated treatment with Leqembi in the six months since traditional approval, demonstrating significant market adoption. Leqembi is an amyloid beta-directed antibody that works by clearing amyloid plaques from the brain. The companies have established a comprehensive patient support program to help navigate the treatment process, including amyloid testing and ARIA monitoring. Biogen and Eisai continue to work with payers to ensure broad insurance coverage for Leqembi.